Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ UWMC Announces Strategic Acquisition of TWO (Business Wire) +++ TWO HARBORS Aktie +6,79%

ASTELLAS ADR Aktie

>ASTELLAS ADR Performance
1 Woche: +8,3%
1 Monat: +15,8%
3 Monate: +24,5%
6 Monate: +42,7%
1 Jahr: +23,8%
laufendes Jahr: +29,3%
>ASTELLAS ADR Aktie
Name:  ASTELLAS PHARMA UNSP.ADR
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US04623U1025 / A0YGQP
Symbol/ Ticker:  YPHA (Frankfurt)
Kürzel:  FRA:YPHA, ETR:YPHA, YPHA:GR
Index:  -
Webseite:  https://www.astellas.com/
Profil:  Astellas Pharma Inc. is a prominent player in the ..
>Volltext..
Marktkapitalisierung:  20186.01 Mio. EUR
Unternehmenswert:  22668.16 Mio. EUR
Umsatz:  11555.23 Mio. EUR
EBITDA:  3183.8 Mio. EUR
Nettogewinn:  719.01 Mio. EUR
Gewinn je Aktie:  0.4 EUR
Schulden:  4264.02 Mio. EUR
Liquide Mittel:  1652.86 Mio. EUR
Operativer Cashflow:  2334.45 Mio. EUR
Bargeldquote:  0.22
Umsatzwachstum:  13.24%
Gewinnwachstum:  128.09%
Dividende je Aktie:  0.44 EUR
Dividendenrendite:  3.71%
Dividendenschätzung:  3.81%
Div. Historie:  30.09.25 - 0.21526635€
31.03.25 - 0.22073507€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ASTELLAS ADR, ASTELLAS
Letzte Datenerhebung:  17.12.25
>ASTELLAS ADR Kennzahlen
Aktien/ Unternehmen:
Aktien: 1791.21 Mio. St.
Frei handelbar: 95.74%
Leerverk. Aktien: -
Rückkaufquote: 0.02%
Mitarbeiter: 13643
Umsatz/Mitarb.: 0.8 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: -8.56%
Bewertung:
KGV: 29.63
KGV lG: 21.32
KUV: 1.83
KBV: 2.28
PEG-Ratio: 0.23
EV/EBITDA: 7.12
Rentabilität:
Bruttomarge: 74.65%
Gewinnmarge: 6.22%
Operative Marge: 17.89%
Managementeffizenz:
Gesamtkaprendite: 3.61%
Eigenkaprendite: 7.95%
>ASTELLAS ADR Peer Group

Es sind 599 Aktien bekannt.
 
17.12.25 - 13:30
 Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.12.25 - 00:33
 Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium (PR Newswire)
 
- Data reflect new insights and precision oncology advancements in portfolio and pipeline - - Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (GEJ) cancer featured in late-breaking......
05.12.25 - 14:03
 Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting (PR Newswire)
 
- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3 MORPHO trial in the post-transplant maintenance setting and Phase 1/2 VICEROY trial in......
01.12.25 - 03:06
 EMA Validates Review Of Astellas′ PADCEV And KEYTRUDA Combination In Bladder Cancer (AFX)
 
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, 4503.T) announced that the European Medicines Agency (EMA) has validated for review a Type II variation application for PADCEV (enfortumab vedotin). ......
22.11.25 - 05:24
 Pfizer: FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (AFX)
 
KENILWORTH (NJ) (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a N......
30.10.25 - 12:48
 Astellas Pharma gives H1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.10.25 - 09:12
 Astellas Pharma H1 Net Profit Surges, Revenue Improves; Lifts Annual Outlook (AFX)
 
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, 4503.T), a Japanese pharmaceutical company, on Thursday reported a surge in net profit for the first half. In addition, the company has revised up it......
22.10.25 - 16:48
 Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study (AFX)
 
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY.PK), Wednesday announced new real-world preliminary data from the OPTION-VMS Phase IV study, a longitudinal, observational study in participants with ......
20.10.25 - 04:36
 Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study (AFX)
 
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination wi......
20.10.25 - 04:00
 Astellas Reports Sustained GA Reduction With Long-Term IZERVAY Treatment In GATHER2 Extension Study (AFX)
 
TOKYO (dpa-AFX) - Astellas Pharma Inc. announced the first results from the open-label extension (OLE) of its Phase 3 GATHER2 study, revealing that monthly treatment with IZERVAY (avacincaptad peg......
15.10.25 - 02:03
 Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society (PR Newswire)
 
TOKYO, Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be......
14.10.25 - 10:24
 Astellas′ Phase 2 Study GLEAM Study Of Zolbetuximab In Pancreatic Cancer Misses Primary Endpoint (AFX)
 
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) on Tuesday said the Phase 2 GLEAM study of zolbetuximab in metastatic pancreatic cancer failed to meet its primary endpoint of overall survival (OS).......
09.10.25 - 13:06
 Biopharma Leaders Advance the Future of Life Sciences at Veeva Commercial Summit Europe (PR Newswire)
 
Industry gathers to explore Veeva AI innovations and exchange ideas with companies including Astellas, Bayer AG, Boehringer Ingelheim, LEO Pharma, Moderna, and MSD BARCELONA, Spain, Oct. 9, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Astellas, Bayer AG, Boehringer......
09.10.25 - 01:30
 Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting (PR Newswire)
 
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas")......
01.10.25 - 08:03
 Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025 (PR Newswire)
 
- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in......
29.09.25 - 08:03
 Astellas Announces Top Management Personnel Change (PR Newswire)
 
TOKYO, Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its Top Management structure, effective October 1, 2025. Nick Eshkenazi, current Chief Digital & Transformation Officer (CDTO),......
29.09.25 - 05:03
 XFRA: DIVIDEND/INTEREST INFORMATION - 30.09.2025 - US04623U1025 (XETRA)
 
Das Instrument YPHA US04623U1025 ASTELLAS PHARMA UNSP.ADR EQUITY wird cum Dividende/Zinsen gehandelt am 29.09.2025 und ex Dividende/Zinsen am 30.09.2025 The instrument YPHA US04623U1025 ASTELLAS PHARMA UNSP.ADR EQUITY has its pre-dividend/interest day on 29.09.2025 and its ex-dividend/interest day on 30.09.2025...
12.08.25 - 13:00
 Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.08.25 - 11:48
 Pfizer′s Padcev Plus Keytruda Extends Bladder Cancer Survival (Bloomberg)
 
The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.'s blockbuster immunotherapy Keytruda extended the lives of patients with a hard-to-treat form of the disease....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!